Quercitrin

Quercitrin

SCHEMBL1697151

C[C@H]1O[C@@H](Oc2c(-c3ccc(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 7/20 1.00
KDM4E B2RXH2 6/20 1.00
L3MBTL1 Q9Y468 4/20 1.00
MAOA P21397 4/20 1.00
EPHX2 P34913 4/20 1.00
XDH P47989 4/20 1.00
SLCO2B1 O94956 4/20 1.00
AKR1B1 P15121 3/20 1.00
PIM2 Q9P1W9 2/20 1.00
ALDH1A1 P00352 2/20 1.00
CA12 O43570 2/20 1.00
CA2 P00918 2/20 1.00
CA4 P22748 2/20 1.00
CA7 P43166 2/20 1.00
NQO2 P16083 1/20 0.85
MAPT P10636 5/20 0.84
POLB P06746 4/20 0.84
GAA P10253 4/20 0.84
KDM1A O60341 2/20 0.84
HMGB1 P09429 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercitrin SCHEMBL29454400 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL117644 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL5456136 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL4227921 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL17628907 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL811472 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL6849807 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL15337986 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL3206092 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2
Quercitrin SCHEMBL29381705 1.00 P4HB (1.00) P4HBKDM4EL3MBTL1MAOAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141253-B1 COMPATIBLE COMPOSITION CONTAINING CHINESE MEDICINE CICHORIUM GLANDULOSUM BOISS ET HOUT AS LIPID-LOWERING ACTIVE INGREDIENT NANJING RUIYING RUNZE BIOPHARMACEUTICAL TECH CO INC (CN) 2019-10-02 EP claimed
EP-1300084-B1 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves BOEHRINGER INGELHEIM INT (DE) 2006-04-19 EP claimed
EP-1225810-B1 METHOD FOR TREATMENT OF CHRONIC VENOUS INSUFFICIENCIES USING AN EXTRACT OF RED VINE LEAVES BOEHRINGER INGELHEIM INT (DE) 2003-03-26 EP claimed
US-10391113-B2 Compatible composition containing chinese medicine cichorium glandulosum boiss et hout as lipid-lowering active ingredient NANJING RUIYING RUNZE BIOPHARMAEUTICAL TECHNOLOGY CO., INC. (CN) 2019-08-27 US disclosed
US-20170100421-A1 Compatible Composition Containing Chinese Medicine Cichorium Glandulosum Boiss Et Hout As Lipid-Lowering Active Ingredient NANJING RUIYING RUNZE BIOPHARMACEUTICAL TECHNOLOGY CO., INC. (CN) 2017-04-13 US disclosed
EP-3141253-A1 COMPATIBLE COMPOSITION CONTAINING CHINESE MEDICINE CICHORIUM GLANDULOSUM BOISS ET HOUT AS LIPID-LOWERING ACTIVE INGREDIENT Nanjing Ruiying Runze Biopharmaceutical Technology Co., Inc. (CN) 2017-03-15 EP disclosed
EP-2575844-B1 Method for producing an enriched extract from vine plants FINZELBERG GMBH & CO KG (DE) 2016-11-23 EP disclosed
WO-2015169122-A1 COMPATIBLE COMPOSITION CONTAINING CHINESE MEDICINE CICHORIUM GLANDULOSUM BOISS ET HOUT AS LIPID-LOWERING ACTIVE INGREDIENT 南京睿鹰润泽生物医药科技有限公司 2015-11-12 WO disclosed
EP-2575844-A1 PROCESS FOR THE PREPARATION OF AN ENRICHED EXTRACT FROM GRAPE VINE PLANT LEAVES Finzelberg GmbH & Co. KG (DE) 2013-04-10 EP disclosed
WO-2011147989-A1 PROCESS FOR THE PREPARATION OF AN ENRICHED EXTRACT FROM GRAPE VINE PLANT LEAVES FINZELBERG GMBH & CO. KG (DE) 2011-12-01 WO disclosed
EP-2161025-A1 Method for producing an extract from vegetable material of the type Rumex acetosa L. Engelhard Arzneimittel GmbH & Co. KG (DE) 2010-03-10 EP disclosed
WO-2006090206-A1 IMPROVED EXTRACTS OF PSIDIUM GUAJAVA L., METHODS FOR ITS OBTAINING AND USE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS LOZOYA LEGORRETA XAVIER (MX) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170100421-A1 Compatible Composition Containing Chinese Medicine Cichorium Glandulosum Boiss Et Hout As Lipid-Lowering Active Ingredient CPT1A, HMGCR, SLC2A8 P4HB 3119/4885KDM4E 3147/4885L3MBTL1 1476/4885
US-10391113-B2 Compatible composition containing chinese medicine cichorium glandulosum boiss et hout as lipid-lowering active ingredient CPT1A, HMGCR, SLC2A8 P4HB 3119/4885KDM4E 3147/4885L3MBTL1 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.